Nasdaq

Kura Oncology and Kyowa Kirin Announce KOMET-001 Trial Results for Ziftomenib in R/R NPM1-m AML Selected for ASCO Presentation

Kura Oncology announces oral presentation of ziftomenib trial results for R/R NPM1-m AML at ASCO 2025, with investor event. Kura Oncology and Kyowa Kirin have announced that an abstract detailing the ...
Business Insider

NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)

Company is usingits Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for patients with relapsed and/or refractory hematologic malignancies GAITHERSBURG, Md.
BioWorld

BVX-001 induces significant tumor regressions in a large tumor murine model of AML

Bivictrix Therapeutics plc has released promising final data from a second in vivo efficacy study of its lead clinical candidate BVX-001, a first-in-class Bi-Cygni antibody-drug conjugate (ADC) for ...
ascopubs.org

An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT).

Comparison of characteristics and prognostic impact of FUS-ERG and AML1-MTG16 fusion genes in adult AML patients: A retrospective study from 1988 to 2022 with a medical database. This is an ASCO ...
Seeking Alpha

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

- NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3 treatment related events as of May 2023 - Robust immune response with clinical activity at the highest dose level ...